Skip to main content
Premium Trial:

Request an Annual Quote

Modest Gain This Week for the BCW Index

The BCW Index rose .9 percent for the week ended Tuesday, outgaining the Nasdaq, which rose .2 percent for the tracking period, and the Nasdaq Biotech Index, which climbed .7 percent. The Dow Jones Industrial Average declined .3 percent.

Shares of Bruker BioSciences rose 4.3 percent to lead the Index, while Harvard Bioscience continued its recent ascent with a 4 percent gain for the week. Only four firms in the Index posted declines this week, led by a 1.7 percent dip for Bio-Rad Laboratories.

BioCommerce Week Index of Diversified Molecular Biology Tool Companies
Company
Ticker
Current Price
(Dec. 13, 2005)
Last Price
(Dec. 6, 2005)
% change
Agilent
A
35.98
34.94
2.98
Applied Biosystems
ABI
27.57
27.34
0.84
Beckman
BEC
57.22
55.73
2.67
Bio-Rad
BIO
60.14
61.19
-1.72
Bruker
BRKR
5.4
5.18
4.25
Fisher Scientific
FSH
64.52
63.34
1.86
GE
GE
35.47
35.8
-0.92
Harvard Bio
HBIO
4.69
4.51
3.99
Invitrogen
IVGN
66.56
65.6
1.46
Molecular Devices
MDCC
28.21
28.02
0.68
PerkinElmer
PKI
23.4
23.06
1.47
Qiagen
QGEN
11.67
11.36
2.73
Sigma
SIAL
65.2
65.41
-0.32
Stratagene
STGN
10.69
10.49
1.91
Thermo
TMO
30.76
31.25
-1.57
Waters
WAT
39.29
38.55
1.92
BCW Index Average
35.42
35.11
0.89
The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.